arrow_back Back to App

Combating Illicit Xylazine: New Regulations and Penalties

This act aims to combat the growing problem of illicit xylazine use, often mixed with other drugs. It prohibits its use in humans and strengthens penalties for illegal distribution. The goal is to protect public health and reduce negative impacts on citizens.
Key points
Prohibition of Xylazine Use in Humans: Any use of xylazine in humans becomes illegal, aiming to protect against severe health consequences like respiratory depression, unconsciousness, or tissue necrosis.
Stricter Penalties for Illicit Trafficking: Individuals illegally distributing xylazine will face harsher penalties, similar to those for trafficking other controlled substances.
Monitoring and Reporting: The government will monitor the spread of illicit xylazine and regularly report to Congress to assess the effectiveness of measures and potentially introduce further changes.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_1839
Sponsor: Rep. Panetta, Jimmy [D-CA-19]
Process start date: 2023-03-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Combating Illicit Xylazine Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_1839.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-03-28.

What are the main provisions?

Key points include:

  • Prohibition of Xylazine Use in Humans: Any use of xylazine in humans becomes illegal, aiming to protect against severe health consequences like respiratory depression, unconsciousness, or tissue necrosis.
  • Stricter Penalties for Illicit Trafficking: Individuals illegally distributing xylazine will face harsher penalties, similar to those for trafficking other controlled substances.
  • Monitoring and Reporting: The government will monitor the spread of illicit xylazine and regularly report to Congress to assess the effectiveness of measures and potentially introduce further changes.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Panetta, Jimmy [D-CA-19].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-24.

CATEGORIES

Health Courts and Law Security